How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
Authors
Bloch, Evan MTobian, Aaron A R
Shoham, Shmuel
Hanley, Daniel F
Gniadek, Thomas J
Cachay, Edward R
Meisenberg, Barry R
Kafka, Kimberly
Marshall, Christi
Heath, Sonya L
Shenoy, Aarthi
Paxton, James H
Levine, Adam
Forthal, Donald
Fukuta, Yuriko
Huaman, Moises A
Ziman, Alyssa
Adamski, Jill
Gerber, Jonathan
Cruser, Daniel
Kassaye, Seble G
Mosnaim, Giselle S
Patel, Bela
Metcalf, Ryan A
Anjan, Shweta
Reisler, Ronald B
Yarava, Anusha
Lane, Karen
McBee, Nichol
Gawad, Amy
Raval, Jay S
Zand, Martin
Abinante, Matthew
Broderick, Patrick B
Casadevall, Arturo
Sullivan, David
Gebo, Kelly A
UMass Chan Affiliations
MedicineDocument Type
Journal ArticlePublication Date
2022-04-04
Metadata
Show full item recordAbstract
Convalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID-19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID-19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID-19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody-based therapies.Source
Bloch EM, Tobian AAR, Shoham S, Hanley DF, Gniadek TJ, Cachay ER, Meisenberg BR, Kafka K, Marshall C, Heath SL, Shenoy A, Paxton JH, Levine A, Forthal D, Fukuta Y, Huaman MA, Ziman A, Adamski J, Gerber J, Cruser D, Kassaye SG, Mosnaim GS, Patel B, Metcalf RA, Anjan S, Reisler RB, Yarava A, Lane K, McBee N, Gawad A, Raval JS, Zand M, Abinante M, Broderick PB, Casadevall A, Sullivan D, Gebo KA. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? Transfusion. 2022 May;62(5):933-941. doi: 10.1111/trf.16871. Epub 2022 Apr 4. PMID: 35352362; PMCID: PMC9086144.DOI
10.1111/trf.16871Permanent Link to this Item
http://hdl.handle.net/20.500.14038/51540PubMed ID
35352362Rights
© 2022 AABB.ae974a485f413a2113503eed53cd6c53
10.1111/trf.16871